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Abstract
Nuclear receptors (NRs) belong to a superfamily of transcription factors that regulate numerous homeostatic, metabolic and
reproductive processes. Taken together with their modulation by small lipophilic molecules, they also represent an
important and successful class of drug targets. Although many NRs have been targeted successfully, the majority have not,
and one third are still orphans. Here we report the development of an in vivo GFP-based reporter system suitable for
monitoring NR activities in all cells and tissues using live zebrafish (Danio rerio). The human NR fusion proteins used also
contain a new affinity tag cassette allowing the purification of receptors with bound molecules from responsive tissues. We
show that these constructs 1) respond as expected to endogenous zebrafish hormones and cofactors, 2) facilitate efficient
receptor and cofactor purification, 3) respond robustly to NR hormones and drugs and 4) yield readily quantifiable signals.
Transgenic lines representing the majority of human NRs have been established and are available for the investigation of
tissue- and isoform-specific ligands and cofactors.
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Introduction
Nuclear receptors (NRs) are ligand-activated transcription
factors that regulate the expression of specific gene networks by
recruiting co-activator or co-repressor complexes. In doing so,
they regulate diverse physiological processes such as metabolism,
development, growth and reproduction. NRs share a modular
structure, which includes highly conserved DNA- and ligand-
binding domains (DBDs, LBDs) spaced by a variable hinge region
[1,2]. Their activities are modulated by small hydrophobic
compounds, such as steroids, fatty acids, retinoids and thyroid
hormones. Ligand binding to the LBD alters its conformation,
cofactor binding and/or transcriptional activity [3]. About a third
of NRs, however, are referred to as orphan receptors, as the
identities of their natural ligands are still unknown.
NR ligands, or drugs that mimic them, have been used to deal
with many major and debilitating diseases [4,5,6]. However, only
a small percentage of NRs have been targeted, and even for these,
drugs that act more selectively would provide huge benefits. New
drugs capable of modulating orphan NR activities have the
potential to control numerous additional disorders such as heart
disease, atherosclerosis, metabolic disease, cancer, inflammation,
depression and anxiety [7,8].
Currently used methods to analyze NR activities and to identify
their ligands are mainly in vitro- or cell culture-based. There are
two major drawbacks of these approaches. First, they fail to predict
the in vivo delivery, stability and specificity of these molecules
within the human body. Second, they only assess a single
molecular interaction or cell type, while other tissue-specific
ligands, cofactors and conditions are ignored. These issues could
be greatly reduced by the adoption of in vivo screening approaches.
However, initial attempts, using b-galactosidase-based reporter
systems [9,10,11,12] have proven tedious, due to a requirement
for tissue fixation, and in vertebrates, dissection or serial
sectioning. More recently, the adoption of fluorescent reporters,
such as the Green Fluorescent Protein (GFP), has allowed the
monitoring of live tissues [9,10,11,13,14]. By combining this use of
flurescent reporters, together with a transparent and ex-utero
developing organism such as the zebrafish, has now made it
possible to design fluorescent reporter systems in live vertebrates.
Zebrafish constitute a powerful animal model, due largely to
their small size, optical clarity, ex-utero development, fecundity,
rapid development and large arsenal of readily available genetic
tools. Importantly, embryos, hatchlings and mature fish readily
absorb/intake compounds from their aqueous environment and
are DMSO tolerant [15,16]. Vertebrate NRs, cofactors and
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9797ligands are highly related, such that in most examined cases,
mutual ligand responsiveness has been observed [17,18]. Devel-
opmental profiling of zebrafish expression patterns [19] has also
demonstrated a high degree of conservation between NR
expression patterns in zebrafish and other vertebrate models.
The concepts underlying the screening technology described
here were derived from previous studies conducted within the
fruitfly, Drosophila melanogaster. In one of these studies [20], we
showed it was possible to use fusions between the fly NR ligand
binding domains (LBDs) and the DBD of Gal4 to visualize NR
ligand and cofactor responsiveness in live animals using a Gal4-
dependent GFP reporter. Two other studies, in which the NRs
E75 [21] and DHNF4 [22] were affinity purified from insect cells
or tissues, suggested that it might be possible to identify bound
ligands using newly developed mass spectrometry techniques,
provided that sufficient amounts and purities of the bound proteins
could be achieved.
Here, we describe a unique combination of NR ligand sensor
and affinity chromatography technologies within a vertebrate
model. Using our TRb and PPARc lines, we show that they
respond within different tissues to endogenous hormones and
cofactors, as well as to exogenously added drugs. We also
demonstrate the potential of our affinity purification system by
isolating a transgenic receptor from zebrafish embryos and
validating the function of one of the co-purified cofactors. We
refer to our combination of technologies, within a pharmacolog-
ically receptive zebrafish model, as the ‘‘ligand trap’’ system.
Results
Assembly of the ‘ligand trap’ (LT) vector
Construction of the ligand trap (LT) vector (Figure 1a) involved
an extensive series of sub-cloning events and configuration
comparisons, with the chosen vector described below. The 3X
FLAG [23], Strep II [24] and 6X His tags were combined into a
single triple-tag cassette, collectively referred to as the ‘FSH’-tag,
and inserted in front of a minimal GAL4 DNA-binding domain
(DBD: residues 1–132). Following the Gal4 DBD sequence, a
series of restriction sites, was used for the in-frame addition of NR
cDNAs (hinge + LBD). To reduce potential lethality that might be
caused by constitutive expression of the GAL4-LBD fusion
proteins, a zebrafish heat shock 70 gene promoter [25] was used
for inducible expression in any tissue and at any developmental
stage. Unique restriction sites flanking the hsp70 promoter can be
used to swap in tissue-specific promoters, if so desired.
Also within the vector is an enhanced GFP (eGFP; includes a
nuclear localization signal) reporter gene that is expressed under
the control of a 14x UASGAL4-containing promoter. Expression of
this reporter requires binding and activation of the Gal4-NR-LBD
fusion protein. Bracketing the GAL-LBD fusion gene and the
Figure 1. The Ligand Trap (LT) system. (a) Schematic diagram of the multi-component ligand trap (LT) construct. Upon heat pulse, the zebrafish
hsp70 promoter directs ubiquitous expression of the GAL4 DNA-binding domain (DBD) fused in-frame to a human nuclear receptor ligand-binding
domain (LBD) and an affinity tag cassette (FSH-tag). Upon binding of this fusion protein to the GAL4 UAS (upstream activating sequence) response
elements, in the presence of active hormone and cofactors, expression of the reporter gene (nuclear enhanced Green Fluorescent Protein (eGFP))
occurs. Expression of nuclear GFP is used to monitor receptor ligand sensor activity in a cell- and tissue autonomous manner in live zebrafish. The
second component makes use of the tags to co-purify bound hormones or cofactors. I = insulator elements; pA = polyadenylation signal; NLS =
nuclear localization signal. (b) Western blots of GAL4-NR fusion proteins. Embryos (F2; 72 hpf) were heat pulsed for 30 min at 37uC and recovered for
1 h at room temperature. 10 embryos were pooled and lysed in 50 ml of FSH buffer (see material and methods) followed by adding SDS buffer and
boiling. Proteins were detected using the FLAG-M2 antibody. (c) Time course of fusion protein expression. TRb embryos (F2; 72 hpf) were heat
induced as in 1b) and recovered for the times indicated. Each sample contained 10 embryos.
doi:10.1371/journal.pone.0009797.g001
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discourage the influence of neighboring gene regulatory elements.
Finally, I-SceI meganuclease recognition sites were added at the
ends of the vector to facilitate integration into the genomes of
transgene and meganuclease co-injected one-cell stage embryos
[26].
Induction of LT fusion protein expression
To test the heat inducible expression and activity of LT fusion
proteins, and to determine the best parameters for activity
screening, we generated stable transgenic lines for each human
nuclear receptor by co-injecting the LT-vector together with SceI
meganuclease into one-cell stage zebrafish embryos. Injected F0
fish were raised to adulthood and crossed with wild type fish to
identify germline transformed animals. Positive progeny (F1) were
identified either by target PCR or GFP screening (see Material and
Methods). At least two independent lines for each nuclear receptor
were obtained, unless otherwise noted. Transgenic LT embryos
(F2) were heat pulsed at different developmental stages, temper-
atures and durations. Western blot detection using a M2-Flag
antibody that recognizes the FSH-tag of each LT fusion protein
revealed uniquely sized proteins with expected molecular weights
(Figure 1b). Figure 1c shows the robust expression observed in
homozygous transgenic (F2) Thyroid Receptor-b (TRb; NR1A2)
embryos at successive time points following a temperature shift to
37uC. As with most LT fusion proteins, peak expression was
observed ,1 hr following the heat pulse (Figure 1c). A thirty
minute heat pulse at 37uC also proved adequate for the production
of robust GFP fluorescence in the presence of endogenous or
exogenously added ligands (see below).
LT fusion proteins interact with fish ligands and cofactors
Different NR-derived lines should exhibit unique GFP
responses during development in response to their respective
ligand and cofactor distributions. To verify this, we induced
expression of our Peroxisome Proliferator-Activated Receptor-
gamma (PPARc; NR1C3), Retinoic acid-related Orphan Recep-
tor-gamma (RORc: NR1F3), Neuron-derived Orphan Receptor-
1 (NOR1: NR4A3) and Rev-erb alpha (Rev-erba:N R 1 D 1 )
transgenic lines and documented their patterns of GFP
expression. The PPARc embryos show strong GFP expression
in the tail bud epidermis, as well as the brain, posterior spinal
cord and heart (Figure 2; left panel). RORc embryos show
ubiquitous GFP expression over the entire embryonic epidermis
during the first three days of development, along with brain and
retina later on (Figure 2 middle panel). GFP expression in NOR1
embryos occurs in the epidermis and CNS (Figure 2; upper right
picture). In contrast, Rev-erba LT embryos show no GFP
expression (Figure 2; lower right), consistent with its role as a
transcriptional repressor [27].
To verify that GFP expression effectively reflects endogenous
signaling activity, we injected a morpholino (MO) oligo-nucleo-
tide, complementary to the translational start site of the transgene,
into one-cell stage PPARc, RORc and TRb embryos (Figure S1).
GFP expression was lost or dramatically reduced in these MO
injected embryos, even in the presence of control agonist.
Further documentation of these sites of hormone activity, and
those of the other LT lines, should provide many new insights into
novel NR functions and relationships during development. They
will also serve as useful tools to genetically and chemically probe
corresponding cellular and developmental processes, and to mark
cells and tissues for co-expression and lineage analyses.
Purification of an in vivo TRb protein complex from early
stage embryos
While a large number of nuclear receptor cofactors have been
identified, their means of identification have generally been limited
to immunoprecipitation from cultured cell extracts or yeast two-
hybrid screens. The ability to identify cofactors throughout
development or in different tissues where NRs are responding to
unique cofactors, and/or ligands, would lead to the identification
of many new cofactors, cofactor complexes and associated
functions. To validate the usefulness of our tags, we induced
expression of the TRb fusion protein in 5–7 hpf embryos
(Blastula/Gastrula stage) and purified the receptor protein
complex from a whole embryo extract (see Methods for details).
Figure 2. Human NRs interact with fish ligands and cofactors. Transgenic NR zebrafish show unique GFP patterns at different stages of
development. Activity patterns of the PPARc (first panel), RORc (middle panel), NOR1 (upper right picture) and Rev-erba (lower right picture) LT
constructs. Embryos were heat pulsed at 37uC for 30 min and images taken 24 h later. PPARc (48 hpf, F2) embryos show GFP expression in cells of
the epidermis and heart, as well as in the posterior spinal cord. Strong GFP expression occurs in the epidermis and retina of RORc embryos (72 hpf,
F2). NOR1 embryos (F3) express GFP in the posterior spinal cord, hatching gland, epidermis and yolk syncictial layer (24 hpf, F2). Rev-erba embryos
show no GFP expression. Overlay pictures of bright field and GFP (75% transparent) are shown. Views are lateral with anterior to the left.
doi:10.1371/journal.pone.0009797.g002
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elution of the TRb purification. Several proteins (bands 1–5) in
addition to the bait protein (band 6; Gal-hTRb) can readily be
seen. These and others were identified by MALDI-ToF and
Orbitrap mass spectrometry (Dataset S1). Identified proteins
included several known nuclear receptor interacting proteins, such
as specific heat shock proteins and lung resistance protein [28,29].
Nuclear proteins were in less abundance, due most likely to the use
of whole cell extracts for this purification.
To test the validity and relevance of one of the novel TRb
cofactors identified, we focused on the protein Homeodomain-
interacting Protein Kinase 3 (HIPK3). HIPK3 is a Ser/Thr kinase
that affects transcriptional regulation, cell differentiation, growth
and apoptosis [30,31,32,33]. Notably, it has already been shown to
bind and modulate two other NRs; Steroidogenic Factor-1 (SF1)
and Androgen Receptor (AR) [30,31].
Western blot analysis of the zebrafish extract and purified
fractions (Figure 3b) confirms the presence of HIPK3 in the
elution. Clearly though, the majority of HIPK3 present in the
whole animal extract is not bound to the TRb bait protein,
consistent with its enzymatic participation in numerous other
protein complexes.
The specificity and nature of this interaction was also tested
using transiently expressed GAL, GAL-TRb or GAL-TRbDAF2
fusion proteins. The latter protein lacks the C-terminal AF2 helix,
which is required for co-activator binding. The fusion proteins
were expressed together with HIPK3 in human HEK 293 cells.
Both full-length and AF2-deleted GAL-TRb fusion proteins were
able to pull down the HIPK3 protein (Figure 3c). Although the
intensity of the HIPK3 band co-purified by the TRbDAF2 deleted
protein appears less intense, this is largely due to the presence of
additional co-migrating bands in the full-length TRb pull down,
which may be due to subsequent modifications of the non-deleted
LBD protein. We conclude that the AF-2 helix is not required for
HIPK3 complex formation.
HipK3 negatively modulates TRb transcriptional activity
Ligand activation of TR is associated with the displacement of
co-repressors and recruitment of co-activators. To investigate
whether HIPK3 affects the transcriptional activity of TRb, a cell
culture co-transfection assay was employed using Gal4-TRb and
Gal-TRbDAF-2 fusion protein. Deletion of the AF2 domain of TRb
results in continued co-repressor binding even in the presence of
hormone, a phenomenon referred to as ‘Resistance to Thyroid
Hormone’ (RTH) [34]. This type of deletion represents the most
severe genetic form of RTH.
Addition of the thyroid hormone analog, TRIAC (3,5,39-
triiodothyroacetic acid) strongly stimulates the activity of the full
LBD fusion protein, but has no effect on the non-activating AF2-
deleted form (Figure 3d). Addition of HIPK3 led to a modest
(,1.3X) increase in the transcriptional activation activity of the
WT fusion protein (Figure 3d). No effect was seen upon addition of
HIPK3 on the activation activity of the AF2 deleted protein,
consistent with the need for the AF2 motif for agonist-based
transcriptional activation.
As TRb represses the expression of target genes in the absence
of hormone, we also looked for effects of HIPK3 on Gal4-LBD
fusion protein activity using a reporter plasmid with significant
basal transcription activity, making it suitable for the observation
of repression (Figure 3e and Figure S2a). As with the transcrip-
tional activation assay with ligand present, HIPK3 had only a
modest affect on GAL4-TRb activity (,1.3X lower). However,
with the AF2 removed, HIPK3 increased transcriptional repres-
sion by an impressive 5–6 fold. This suggests that HIPK3 acts
primarily as an enhancer of TRb- mediated transcriptional
repression.
To further probe the mechanistic nature of this HIPK3 affect,
we examined its ability to augment repression mediated by the
known TRb co-repressor, N-CoR [35,36,37]. Co-expression of
HIPK3 or N-CoR with the WT TRb fusion protein increased
repression of the UAS-containing reporter approximately 4- and
3- fold respectively (Figure 3f and Figure S2b). When added at the
same time, a further ,2-fold increase in repression mediated by
the TRbDAF2 mutant was observed. These interactions and effects
were not observed with a kinase-defective HIPK3 protein
(Figure 3f). These results are consistent with the activities of other
HIPK family members on target gene expression and co-repressor
function [38,39].
Zebrafish ligand trap activities are hormone-inducible
To test whether our LT lines are responsive to externally
provided hormones or drugs, we treated the PPARc line with
readily available agonists and antagonists (Figure 4a–b). PPARc
fish treated with the receptor specific agonists Rosiglitazone
(RGZ), Pioglitazone (PGZ) or Troglitazone (TGZ)) increased the
GFP reporter response from the relatively restricted signal in tail
epidermis and posterior spine to include strong expression in the
CNS, heart, blood, renal tube and eye (Figure 4a). Higher
magnification of the embryo head shows specific and detailed
activation in the presence of drug in the brain, eye and heart
(Figure 4b panels 2 and 4). Older embryos (5–6 dpf) also show
strong GFP expression in other tissues including heart, blood and
intestine (Figure 4b, panels 5–8). Treatment of PPARc fish with
PPARa- or PPARd-specific agonists showed no increase in
reporter activation when used at their receptor-specific EC50
concentrations (Figure S3a). However, as seen in Gal4-PPAR cell
based assays [40], higher concentrations of the beta or alpha
agonist do result in partial activation of the PPARc LT embryos
(Figure S3a). Treatment with the selective PPARc antagonist
GW9662 either decreases or completely blocks the GFP responses
to endogenous ligand(s) (Figure 4b-13 and Figure S3b). When
added together with Rosiglitazone, in a classical agonist/
antagonist competition experiment, GW9662 was clearly able to
displace the potent PPARc agonist (Figure S3b).
As further validation of drug responsiveness, we also treated
TRb fish with known agonists (Figure 4c). Vehicle treated TRb
embryos show the same response seen in untreated embryos. TRb
fish treated with either Thyroxine (T4) or Triiodothyronine (T3)
induced reporter activation in the eye, heart, epidermis, blood,
muscle and brain (Figure 4c). As expected, T3 activates the
reporter more strongly than T4. Treatments with TRIAC, also
yielded strong responses at dosages similar to those used in
mammalian tissues. The eye activity of TRb ligand trap fish
correlates well with previously reported expression of endogenous
TRb in retina at 48 hpf [19]. However, our finding of receptor
activity in other tissues such as the brain and anterior spinal cord
are novel. Interestingly, in a recent profiling of zebrafish NR
expression patterns, Bertrand and colleagues found that nuclear
receptors expressed in the retina, except of TRb, are also
expressed in the brain and/or anterior spinal cord. We expect
that many of the novel activity patterns observed in our LT lines
will represent novel roles in early development, opening the door
for new avenues of study.
LT drug treatments reveal tissue selective nuclear
receptor activities
Recent drug discovery programs have been heavily focused on
the identification of compounds with activities in a subset NR-
Nuclear Receptor In Vivo Model
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9797Figure 3. Co-purification of TRb cofactors. (a) Affinity purification of TRb from zebrafish embryos. Blastula-/Gastrula-stage embryos were heat
induced for 20 min and recovered for 2 h at room temperature. After purification, the eluate was run on an 8% SDS PAGE and then silver stained.
Protein bands (indicated as 1–6) were cut and in gel digested followed by mass spectrometry. Identified protein IDs are shown. M= protein marker.
(b) Immunodetection of HIPK3. Western blotting using a HIPK3 antibody (lower panel) shows that a subfraction of the protein co-purifies with the
Nuclear Receptor In Vivo Model
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yield fewer side effects and have additional uses. Interestingly, each
of the TR agonists tested above exhibited significant tissue-
selective activities, as indicated by the colored arrows in Figure 4c.
For example, T3 and T4 elicited strong GFP responses in dorsal
muscle while TRIAC did not. Conversely, TRIAC elicited
responses in the spinal cord while T3 and T4 did not. Differential
responses were also seen in the eye, heart, epidermis brain and
blood. Many of these sites of action have not been previously
documented.
To further verify that GFP expression in the TRb lines are
ligand- and cofactor-dependent, we made two additional trans-
genic lines carrying mutations in the TRb LBD (Figure 4d). These
include the previously described LT-TRbDAF2 and a construct
carrying a single AF2 point mutation, LT-TRbE457A. Both
mutations result in impaired co-activator recruitment upon ligand
binding [34]. As already shown (Figure 4c), TRb WT embryos
respond strongly to the addition of TRIAC. However, TRIAC-
treated TRbE457A fish show dramatically reduced GFP expression,
with signal restricted mainly to epidermal cells of the tail bud, and
TRbDAF2 embryos show no detectable GFP whatsoever
(Figure 4d). Western blot analysis using anti-FLAG antibody
shows that both fusion proteins are well expressed. We conclude
that the signals observed with these lines are ligand and co-
activator dependent.
GFP signals are readily quantified and suitable for drug
screening
To test whether drug effects can be quantified with our ligand
trap fish, we subjected TRb LT embryos to increasing
concentrations of the agonists T3, TRIAC or KB2115 [41], and
the antagonist Amiodarone. Figure 5a shows a series of tail regions
of the treated TRb embryos. Note that the number and intensity
of GFP responding nuclei increase in proportion to hormone
concentration but decrease again as levels become teratogenic.
Figure 5b shows averaged GFP response curves for increasing
concentrations of all three ligands. TRIAC proved to be the most
effective, then KB2115, and lastly T3. Amiodarone treatment
yielded no detectable GFP response as expected. Importantly our
dose-response curves for the various TRb agonists tested correlate
well with previously determined animal and human data [42,43].
Discussion
We have taken advantage of the unique properties of zebrafish
as a model organism to engineer a powerful in vivo screening
system for new Nuclear Receptor ligands and cofactors (uses
summarized in Figure 6). Embryos and larvae produced by the
transgenic fish are readily arrayed, drugged and assayed within
microtiter plates, making them suitable for high throughput
screens. As discussed below, this whole-animal approach will
facilitate the identification of ligands and cofactors that could not
otherwise be identified by previously used in vitro or cell based
approaches. Many of these ligands and cofactors will act tissue- or
stage-specifically, providing new options for NR study and
manipulation. In turn, the tissue-specific GFP responses produced
by these novel endogenous and exogenous ligands will also
provide the bases for subsequent genetic, molecular and visual
screens that provide new insights into how these tissues develop
and function.
A major problem with current drugs that target NRs is the side-
effects that arise due to unwanted modulation of the targeted NR
in tissues that are not the source of the problem, or to the targeting
of other NR members of the same class. The identification of more
selective compounds that act more NR- and tissue-specifically has
the potential to circumvent these problems. Although such
selective NR modulators (SNRMs) have been discovered, they
are extremely difficult to screen for and new techniques and
models are needed to succeed in the discovery of beneficial new
drugs. With the LT system, known or potential ligands can be
tested in all tissues and during any stage of development. As shown
here, this readily reveals the SNRM properties of all active
compounds.
The LT lines developed here should also be immensely useful
for the identification of ‘endocrine disruptors’ within industrial,
agricultural and municipal wastes [44]. The majority of these
molecules emulate NR ligands, thereby interfering with normal
human and animal development and function. Fish are one of the
major targets and concentrators of endocrine disrupting com-
pounds, and as such, are a highly appropriate test bed for their
presence [45].
Several methods for isolating native protein complexes have
been described in yeast, bacteria, cell culture, plants and insects
[46]. Here, we show that the affinity tag cassette used in the LT
system is capable of purifying protein complexes from whole
vertebrate tissues with sufficient yield and purity for subsequent
cofactor purification and identification. With appropriate modifi-
cations, the identities of bound ligands should also be readily
determined. Indeed, the use of multiple affinity chromatography
steps followed by mass spectrometry has already yielded ligands for
the Drosophila NR E75 [21], and the mouse NR PPARa [47].
Given the number of NRs that remain as orphans, this has great
potential for the timely identification of their recalcitrant ligands.
The ability to identify directly bound ligands also provides a means
to determine whether active compounds identified in compound
screens are directly bound and unmodified. In some cases, the
active molecule may be a metabolite of the original compound
added. Thus, the LT system has the potential to identify ‘pro-
drugs’, something that is difficult or impossible to achieve by other
means.
Our results with TRb suggest that its major role during early
development is primarily as a repressor. This was evidenced by the
lack of GFP activity in the absence of supplemented agonists, and
the isolation of repressive cofactors. Among the novel cofactors
bait protein. Presence of the TRb protein in the same fractions, detected using Flag-M2 antibody, is shown above. (c) HEK293 cells were transfected
with FLAG-HIPK3 and one of three different Gal expression constructs containing the FSH-tag: Gal, Gal-TRb (aa 189–461) and TRbDAF2 (aa 189–451).
After 48 h of transfection, the cells were harvested in IP buffer and Gal and Gal fusion proteins immunoprecipitated using Streptactin Sepharose.
Western blotting using a FLAG M2 antibody shows HIPK3 in the Gal-TRb and Gal-TRbDAF2 pull downs. (d) Transcriptional activity of TRb proteins. 293
cells were transfected with a 2xUAS-Luciferase reporter construct (0.2 mg/well) and Gal or Gal-TRb constructs (0.05 mg/well): Gal-TRb (aa 189–461) and
TRbDAF2 (aa 189–451) in the presence of 100 nM TRIAC. Fold activation was measured in the presence (0.05 or 0.1 mg/well) or absence of HIPK3.
Luciferase values were normalized against b-Gal. (e) Effects of HIPK3 on Gal-TRb induced repression. 293 cells were transfected with a 2xUAS-
Luciferase reporter construct and either Gal, Gal-TRb or GAL-TRbDAF2. Fold repression was measured in the presence or absence of HIPK3. Luciferase
values were normalized against b-Gal. Transfections as under 3d. (f) The effect of HIPK3 was investigated in the absence or presence of the co-
repressor N-CoR. Transfections were performed as in 3d using the Gal-TRbDAF2 (aa 189–451) construct. Fold repression of the TRb mutant in the
presence of HIPK3 and/or N-CoR (0.05 mg/well) are shown.
doi:10.1371/journal.pone.0009797.g003
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9797Figure 4. Ligand trap activities are drug responsive and reveal SNRM activities. (a) LT-PPARc embryos show strong reporter activation in
the presence of receptor specific agonist (uses as indicated). After heat pulse followed by overnight incubation with solvent or drug GFP expression
in cells of the epidermis, CNS, eye, blood and heart (48 hpf; lateral view) is induced. Yellow arrow indicates GFP expression in heart. (b) Upper panel
shows magnifications of embryo heads in ventral (b-1-2) and dorsal (b-3-4) orientation of 2 dpf fish treated with solvent or 50 nM Rosiglitazone
(RGZ). B-2 shows reporter expression in eye (e), forebrain (fb), heart (h) and b-4 indicates GFP expression in hindbrain (hb), tectum (t) and anterior
spinal cord (s). Middle panel shows drug responses in tissues of older embryos: Expression in heart (b-5; 5 dpf ventral view), in blood (b-6; 8 dpf), in
the spinal cord (s) and endothelium layer ((el), b-7; 4 dpf, lateral view) and in the intestine ((I, b-8; 6 dpf). Embryos were subjected to a 30 minute heat
pulse at 37uC, followed by incubation with 50 nM Rosiglitazone for 24 h. The lower panels show responses to: endogenous hormone in the tail
epidermis of 3 dpf embryos treated with solvent (b-9); 500 nM Pioglitazone (b-11), 500 nM RGZ (b-12) and treatment with the antagonist GW9662
(500 nM). (c)T R b LT embryos show tissue-specific responses to hormones and drugs. After 40 min heat induction, embryos (24 hpf) were incubated
with compounds for 28 h in a 28uC incubator in the dark. Solvent (Ethanol) treated embryos show no GFP expression. T4 (2.5 mM) treated embryos
show strong reporter activity in muscle and to a lesser amount in epidermis, brain and eye retina. T3 (2.5 mM) treatments result in similar responses
but GFP induction in epidermis, brain and eye is stronger, and signal is also seen in blood cells. TRIAC (100 nM) treatments also induce GFP responses
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potentiator of target gene repression. Given the ligand-indepen-
dent nature of this interaction, it may provide additional means to
treat or circumvent ‘resistance to thyroid hormone’ (RTH)
conditions. Previous studies on HIPK proteins have also shown
important functions during development [48], and in some cases
via interactions with well characterized co-repressors [38]. As the
dissociation and disposal of these co-repressors appears to require
phosphorylation and/or ubiquitination [49,50,51], HIPK3 may be
functioning in a related capacity. It should be noted, however, that
while HIPK3 enhances N-CoR-mediated repression of TRb,i t
has also been shown to mediate ligand dependent transcriptional
activation by the Androgen and SF1 Nuclear Receptors, while
having no apparent effect on Glucocoritcoid Receptor mediated
transcription [30,31]. As such, NR modulation by HIP kinases
may serve as an alternative means of differentially controlling
multiple NR activities.
Taken together, this study shows that the LT system provides
enormous potential for the acceleration of NR functional analyses.
Its amenability to systems biology scale analyses that access all
tissues and developmental processes will reveal many new
unpredictable and unexpected results.
Figure 5. LT drug responses are quantifiable. (a) Dose dependent GFP expression Shown are the dose responses for T3, KB2115 and TRIAC in
TRb tail epidermis (48 hpf) treated embryos. Treatments were done from 0.1–500 nM. GFP images show anterior-posterior tail view (imaged at 1506
magnification) (b) The graph indicates average intensity of GFP signals for each treatment in percent. GFP expression was quantified using nuclei
count software from MetaX files. Values for drug treated fish are shown in yellow (TRIAC), in blue (KB2115) and in red (T3).
doi:10.1371/journal.pone.0009797.g005
in brain, heart, eye, epidermis and muscle, and in addition, anterior spinal cord. Overlay pictures of bright field and GFP (75% transparent) are shown.
Arrows indicate tissue-specific GFP responses: grey = muscle and red = brain. (d)T R b responses in transgenic fish are dependent on a functional
LBD. TRbwt,T R bE457A and TRbdAF2 embryos (24 hfp, F1) were heat pulsed and soaked in TRIAC (100 nM) as described in Figure 4c. The upper row
shows strong (wt), weak (E457A) and no (dAF2) epidermal GFP expression in the tail. Western blot detected proteins show similar levels of TRb
transgene expression (right side).
doi:10.1371/journal.pone.0009797.g004
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pLT plasmid construction
To generate the ligand trap vector, p-LT, we first combined the
SV40 late polyadenlyation site from pCS2+ (cloned XbaI/Hind
III) and the Gal4 DBD (aa 1–132; cloned into XbaI) into
pBluescript (Stratagene). PmeI and NheI restriction sites were
introduced in the primer as cloning sites for NR ligand binding
domains. An EcoRV restriction site was designed N-terminal to
the Gal4DBD for introducing the FSH-triple tag. Oligos for the
triple tag were designed with EcoRI restriction sites on both ends
and annealed together followed cloning into EcoRI digested
pBSII. The tag was then PCR amplified with primers containing
EcoRV restriction sites and a Kozak consensus sequence followed
by an ATG start codon. This fragment was then introduced into
the EcoRV restriction site of pBSGal1-132-pA, resulting in pBS-
tripletag-Gal1-132-pA. Next, two I-SceI mega nuclease recognition
sites were introduced by site directed mutagenesis flanking the
fragment.
The eGFP-NLS gene was PCR amplified from the pUAS
Stinger vector [52] and cloned into pBluescript II containing a
SV40 polyA to generate pB-eGFP-pA. A fragment containing
multi-UAS Gal DBD binding sites followed by the basal
adenovirus promoter, E1b, was PCR amplified from pBUASEIB
[13] and inserted into pB-eGFP-pA. The UASE1b-eGFP-pA
fragment was then cut out by KpnI digestion and cloned into
KpnI digested pB SceI-Tag-Gal1-132-pA. The resulting plasmid
was SacII/NotI cut to insert a SacII/NotI fragment of the
zebrafish Hsp70 promoter amplified from pzHSP70/4prom [25].
Finally, the gypsy insulator elements from the UAS-Stinger GFP
transformation vector were PCR amplified and inserted upstream
of the Hsp70 promoter into SacII restriction sites or downstream
of the eGFP reporter into HindIII/ApaI.
Fish microinjections and maintenance
Zebrafish were maintained at 28.5uC on a 14/10 hour light/
dark cycle and staged according to hours (h) or days (d)
postfertilization [53]. To generate pLT lines, plasmids were pre-
digested with I-SceI (0.8 mg DNA, 1 ml I-SceI (New England
Biolabs) 2 ml 10x I-SceI buffer, 1 ml BSA) for 20 min at 37uC.
Digested DNA was adjusted with 0.1% phenol red. 4.6 nl of DNA
solution was injected into the blastomeres of early one-cell stage
embryos [26]. Morpholino (MO) injection: 4.6 nl of MO
(0.5 mM) in 0.1% phenol red was injected into the one-cell stage.
F0 fish were crossed with WT fish to identify germ-line
transformed animals, as determined by fin cut PCR with GFP
primers or control agonist treatments. F1 progeny showing strong
and consistent GFP responses were selected for F2 homozygote
production. To avoid reporter GFP silencing of stable transgenic
LT lines [54,55], F2 lines showing strong and consistent GFP
responses were selected for continued propagation of the line.
These lines have been maintained for several generations with no
loss of responsiveness. At least two independent stable lines of each
LT construct were generated, however for LT-PPARc only one
germline fish was identified.
All experiments were approved by the institutional review board
at University of Toronto.
Plasmids, cell culture transfection
FSH-Gal1-132 from pLT plasmid (NotI/PmeI) was cloned in
frame into pcDNA3.1 (Invitrogen) to generate pcDNA3 FSH-
GalDBD. The N-CoR plasmid has been described previously [36].
pFLAG-HIPK3 (2–1191) and pFLAG-HIPK3 (K226R) were
provided by J.J. Palvimo (University of Helsinki). The 14xUA-
SE1B plasmid was a gift of Dr. Sue (Banting and Best Department
of Medical Research/originally provided by Dr. R.W. Ko ¨ster;
Helmholtz Zentrum, Germany). The plasmids for reporter gene
assays 2X-GAL4 binding-site luciferase, pSV40 b-Gal) have been
described previously [37,56]. 293 cell line transfections were done
with Lipofectamin
TM 2000 (Invitrogen).
Compound screening
Embryos were heat induced (28R37uC) for 30 minutes and
then arrayed in 24 well plates (10 per well). The water was
removed and 500 ml of embryo water/well including dissolved
small molecules or solvent was added shortly after heat pulse.
Embryos were incubated at 28uC for 14–20 h and then monitored
using a fluorescent dissection scope (SteREO Lumar.V12 Carl
Figure 6. Schematic representation of LT platform functions.
doi:10.1371/journal.pone.0009797.g006
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adult fish were anesthetized with Tricaine (Sigma, Cat.# A-5040).
Embryos were mounted in 1% AgarPlaque PlusTM Agarose (#
21403A) purchased from PharminGen.
Drugs used
Sigma-Aldrich: Amiodarone hydrochloride (A8423); T3
(T2877); T4 (T2376) and TRIAC (T7650); Alexis Biochemicals:
Pioglitazone (ALX-270-367); Cayman Chemicals: Rosiglitazone
(#71740); Troglitazone (#71750); GW 9662 (#70785); KB2115
(#10011054), GW 0742 (#10006798) and GW 590735
(#10009880).
Affinity purification of proteins
Purifications were performed at 4uC. 5-6 hpf LT-TRb embryos
(128 g) were heat induced (37uC) for 20 min and recovered for
2 h. Homogenization was carried out in 100 ml FSH buffer
(100 mM Tris-Cl pH 8, 150 mM NaCl, 0.1% Triton X-100 and
Roche complete Mine protease inhibitor cocktail) including
2.5 mM DTT, 10 nM Avidin and 1 mM EDTA. After 20 min
incubation the lysate was centrifuged for 10 min at 9000 rpm.
15 ml of prewashed (FSH buffer) Agarose-bead slurry (ABT; 2%
plain Agarose beads) was incubated with the centrifugation
supernatant (220 ml) for 30 minutes. After this incubation and
again centrifugation the supernatant (200 ml) was incubated with
5 ml prewashed Strep TactinH (IBA; Cat: 2-1201-0251) slurry for
2 h. After incubation the beads were transferred to 2 gravity
disposable columns (Bio-Spin columns, Cat: 732–6008) and
washed 6 times with 2 ml of FSH-buffer including 1 mM EDTA.
Bound proteins were eluted using volume 0.5 ml of 2.5 mM d-
desthiobiotin containing FSH-buffer and 1 mM EDTA. For triple
step purifications the Strep elutions were incubated for 2 hrs with
FLAG M2 monoclonal antibody matrix (Sigma), and then washed
3times with FSH buffer followed by elution with FSH buffer
containing 300 mg/ml 3x FLAG peptide (Sigma). Flag elutions
were incubated for 1 hrs with 60 ml of Talon beads in an
Eppendorf tube, and then washed two times with FSH buffer
followed elution with 2xSDS buffer. For immunoprecipitations,
HEK 293 cells were grown in 10 cm dishes and DNA (9 mgo f
FLAG-HIPK3 with either 4 mg of pcDNA3-FSH-GAL, -GAL-
TRb or -GAL-TRbDAF2/empty vector was used to adjust the
DNA concentration) was transfected with Lipofectamin following
the manufacturer’s instructions. Cells were harvested in 1 ml IP
buffer (50 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 0,75%
NP-40, 1 mM DTT and Roche complete Mine protease inhibitor
cocktail). After 10 min centrifugation at 13,000 rpm, 600 mlo f
cleared extract was incubated with 100 ml Strep TactinH slurry for
2 h; followed by 3 washes with 1 ml of IP buffer. Immunopre-
cipitated proteins were separated by SDS PAGE and detected by
FLAG-M2 Western blotting.
Western blotting
Expression of ligand trap constructs was verified using a
monoclonal mouse aM2 antibody (dilution 1:10 000; Sigma).
Heat pulsed and recovered transgenic embryos were homogenized
in 5 ml FSH buffer/embryo and denatured with SDS PAGE
loading buffer followed separation on 10% SDS-polyacrylamide
gels. Detection of HIPK3 was done with aHIPK3 from Abgent
(AP 7500b).
Mass spectrometry
Eluted proteins were separated by SDS PAGE, silver stained
and individual bands excised, digested with Trypsin and analyzed
by MALD-TOF or ESI-MS tandem mass spectrometry. All
samples for ESI-MS were analyzed by a 2-hour LC gradient using
a split-free nano-LC (EasyLC, Proxeon, Odense, Denmark)
coupled to a LTQ-Orbitrap XL, as recently described [57].
Raw data was converted to m/z XML using ReAdW and
searched on a Swquest SorcererTM, using both Sequest and
X!Tandem, against a zebrafish IPI protein sequence database
(version 3.38) also containing the protein sequences of known
contaminants (i.e. human keratins) and trypsin and the bait protein
(human thyroid receptor). Searches were performed with a
fragment ion mass tolerance of 0.8 Da and a parent ion tolerance
of 50 ppm. Complete tryptic digestion was assumed. The
iodoacetamide derivative of cysteine was specified in Sequest
and X!Tandem as a fixed modification. The oxidation of
methionine was specified as a variable modification. Scaffold
(version Scaffold 2.1.1, Proteome Software Inc., Portland, OR)
was used to validate MS/MS based peptide and protein
identifications. Peptide identifications were accepted if they could
be established at greater than 95.0% probability as specified by the
Peptide Prophet algorithm and contained at least 1 identified
peptide. Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony.
Oligos used to clone pLT:
pB Gal1-132-pA:
5’ATTCATCTAGAGATATCAAGCTACTGTCTTCTATCGAACA-
AGC 3’ATTATCTAGAGTTTAAACAGCTAGCTGATGATGTCGCA-
CTTATTCTATGC
pB II triple tag:
sense –AATTCGACTACAAAGACCATGACGGTGATTATAAA-
GATCATGACATCG -
ACTACAAGGATGACGATGACAAGGAGAACCTGTACTTCCAGTC-
CAACTGGAGCC -
ACCCGCAGTTCGAAAAGCATCACCATCACCATCACG
-antisense -ATGATCTTTATAATCACCGTCATGGTCTTT-
GTAGTCG
-AGTTGGACTGGAAGTACAGGTTCTCCTTGTCATCGTCATCC-
TTGTAGTCGATGTC
-AATTCGTGATGGTGATGGTGATGCTTTTCGAACTGCGGGTG-
GCTCC
pB triple tag-Gal1-132-pA
5’ ATTATGATATCgccaccatgGACTACAAAGACCATGACGG
3’ ATTATGATATCGTGATGGTGATGGTGATGC
SceI pB triple tag-Gal1-132-pA
T7 5’ GACTCACTATAGGGCTAGGGATAACAGGGTAATGAA-
TTGGGTACCGGG-
T7 3’ CCCGGTACCCAATTCATTACCCTGTTATCCCTAGCCC-
TATAGTGAGTC-
T3 5’ CGGTGGAGCTCCAGTAGGGATAACAGGGTAATCTTTT-
GTTCCCTTTAGTG-
T3 3’ CACTAAAGGGAACAAAAGATTACCCTGTTATCCCTAC-
TGGAGCTCCACCG-
pB eGFP-pA
5’ ATTATCTAGAACCATGGTGAGCAAGGGC
3’ ATTATCTAGATTACTTGTACAAGTAGCG
pB UASE1b-eGFP-pA
5’ ATTATCCGCGGGGTACCCTCCAAGGCGGAGTACTGTCC
3’ ATAATCGGCCGGTGTGGAGGAGCTCAAAGTGAGGC
pLT ; SceI pB zHsp70 triple tag Gal-1-132-pA-UASE1b-eGFP-
pA)
5’ATTATCCGCGGTCAGGGGTGTCGCTTGG 3’ATTATGCGG-
CCGCGATATCGAATTCCTGCAGG
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UASE1b-eGFP-pA)
5’ Hsp ATAACCGCGGTCACGTAATAAGTGTGCG
3’ Hsp ATAACCGCGGAGATCTATACTAGAATTGATCGGC
5’ Gfp ATAAAAGCTT TCACGTAATAAGTGTGCG
3’ Gfp ATAAGGGCCCATACTAGAATTGATCGGC
Morpholino oligo sequence:
5’ to 3’ and complementary to the translational start of the FSH
Gal-NR:
ACCGTCATGGTCTTTGTAGTCCATG
Primes used to clone NR cDNAs:
NR1A2wt/ E457A/ dAF2
5’ ATTAGCTAGCATGACTCCCAACAGTATGAC
NR1A2wt
3’ ATTAGTTTAAACCTAATCCTCGAACACTTCC
NR1A2E457A
3’ ATTAGTTTAAACCTAATCCTCGAACACTGCCAAGAACAAA-
GG
NR1A2dAF2
3’ ATTAGTTTAAACCTACTATTCTGTGGGGCATTCCACC
NR1C3
5’ ATTAGCTAGCGAGAAGGAGAAGCTGTTGG
3’ ATTAGTTTAAACCTAGTACAAGTCCTTGTAGATCTCC
NR1F3
5’ ATTAGCTAGCATGTCCAAGAAGCAGAGGG
3’ ATTAGTTTAAACTCACTTGGACAGCCCCACAGG
NR1D1
5’ ATTAGCTAGCATGCTTGCTGAGATGCAGAGTGCC
3’ ATTAGTTTAAACTCACTGGGCGTCCACCCGGAAGG
NR4A3
5’ GATCGCTAGCCCATTACAACAGGAACCTTCTCAG
3’ CACCGTTTAAACTTAGAAAGGTAGGGTGTCCAGG
Supporting Information
Figure S1 Ligand trap signals are NRs specific A Morpholino
(MO) against the FSH-tag of the GAL-NR transgene was injected
into one-cell stage F3 embryos of LT-PPARc, RORc and LT-
TRb. Endogenous and agonistic drug responses were compared
between control and MO injected embryos. The upper row shows
48 hpf PPARc embryos in their chorions, and tail close ups of the
same conditions are shown in the middle row. The lower row
shows RORc (F2) or homozygous TRb F3 embryos in the
presence of 250 nM T3 with control or MO injections.
Found at: doi:10.1371/journal.pone.0009797.s001 (0.70 MB TIF)
Figure S2 (a/b) Expression of HIPK3 and Gal- and Gal-TR-
fusion proteins in reporter assays (Figure 3e and 3f) verified by
Western Blot using Flag M2 antibody.
Found at: doi:10.1371/journal.pone.0009797.s002 (1.62 MB TIF)
Figure S3 Selective PPARc drug responses (a) At 24 hpf PPARc
embryos were subjected to a 30 minute heat shock at 37uC and
then incubated for 24 hr in the presence of agonists specific for
one of the three PPAR isoforms (Rosiglitazone for c, GW0742 for
d/b and GW9578 or GW590735 for a). The concentrations
chosen represent known EC50 values for the appropriate targets,
along with significantly higher levels to test for cross-reactivity.
Lateral views of 48 hpf embryos, anterior to the left, are shown. (b)
PPARc agonist/antagonist replacement. At 24 hpf PPARc
embryos were subjected to a 30 minute heat induction at 37uC
and either incubated for 24 hr in the presence of solvent or
1000 nM GW9662 (upper row) or 50 nM Rosiglitazone (RGZ)
alone or 50 nM RGZ and increasing concentrations of GW9662
(20 nM and 500 nM). Two embryos for each treatment showing
lateral views at 48 hpf, anterior to the left, are shown.
Found at: doi:10.1371/journal.pone.0009797.s003 (2.76 MB TIF)
Dataset S1 Table of mass spectrometry-identified bait protein
(Gal-hTRb) and interacting proteins are shown. Eluted proteins
were separated by SDS PAGE, silver stained and individual bands
(band 1–6) excised, digested with Trypsin and analyzed by
MALD-TOF or ESI-MS tandem mass spectrometry. Accession
number, molecular weight (MW) and description of identified
proteins are listed. The purified bait (Gal-hTRb) and the
investigated cofactor are underlined in yellow.
Found at: doi:10.1371/journal.pone.0009797.s004 (0.04 MB
XLS)
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